OCUFLOX (ofloxacin)
OCUFLOX is indicated for the treatment of Conjunctivitis; Corneal Ulcer.
Development Insights
Details
- Status
- Prescription
- First Approved
- 1993-07-30
- Routes
- OPHTHALMIC
- Dosage Forms
- SOLUTION/DROPS
OCUFLOX Approval History
What OCUFLOX Treats
2 indicationsOCUFLOX is approved for 2 conditions since its original approval in 1993. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Conjunctivitis
- Corneal Ulcer
OCUFLOX Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to OCUFLOX
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
5 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT03933631 PAACK | 2018-9829 | Ph 3 | recruiting | Pilocarpine Use After Kahook Goniotomy |
| NCT05302531 GRAAL | 2021-001468-13 | Ph 1 | recruiting | Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome |
| NCT04005079 PACCT | 2017-8704 | Ph 3 | withdrawn | Pilocarpine After Combined Cataract/Trabectome Surgery |
| NCT04353362 | Istanbul Medipol | Ph 4 | completed | Alternative Antibiotic Regimen in Periodontitis Treatment |
| NCT01799356 | Asicioglu03 treatment, treatment uPID | Ph 4 | completed | Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
OCUFLOX FDA Label Details
Indications & Usage
FDA Label (PDF)OCUFLOX is indicated for the treatment of Conjunctivitis; Corneal Ulcer.
Track OCUFLOX with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment